Navigation Links
Major gene study uncovers secrets of leukemia

Investigators at St. Jude Children's Research Hospital have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children. The discovery not only suggests novel methods for treating pediatric ALL, but also provides a roadmap for the identification of unsuspected mutations in adult cancers.

ALL is a tumor in which immature white blood cells that normally develop into immune system cells, called B or T lymphocytes, instead multiply rapidly and overwhelm the normal blood cells the body needs to survive.

The St. Jude team used microarrays, postage-stamp-sized chips that contain DNA fragments, which allowed researchers to investigate more than 350,000 markers called single nucleotide polymorphisms. Single nucleotide polymorphisms are individual variations in the DNA that are spaced across the human chromosomes. Single nucleotide polymorphisms function as flags for researchers, allowing them to detect specific deletions of DNA in a gene or increases in the number of specific genes at a level of detail that was previously unattainable. The St. Jude group used this approach to analyze leukemia samples from 242 pediatric patients with ALL. This identified an unexpectedly high frequency of mutations involving genes that function as master regulators of normal B-cell development and differentiation.

A report on this work appears in the March 7 online edition of "Nature."

"The results of our study demonstrate that it is possible to significantly speed the identification of the genetic lesions that are the underlying cause of not only ALL, but also many other cancers, including those affecting adults," said James Downing, M.D., scientific director and chair of the Pathology department at St. Jude. He is senior author of the paper.

The study found that 40 percent of patients with ALL had deletions or mutations in one of three so- called "master genes" that control the normal differentiation of immature progenitor cells into mature B lymphocytes.

The researchers found that the "PAX5" gene was most frequently mutated—altered in about 30 percent of patients. These mutations reduced the level of PAX5 protein in leukemic cells or resulted in the formation of PAX5 protein with defective function. Mutations were also found in other genes with important roles in B-cell differentiation including "EBF1" and "Ikaros."

"Although the identification of such a high frequency of mutations in this pathway was surprising, it is important to note that the approach used provides a lower limit of the true frequency of these mutations, since not every gene in this pathway could be accurately analyzed using this methodology," Downing said.

The mutations identified in "PAX5," "EBF" and "Ikaros" are likely to directly contribute to this block in normal lymphocyte differentiation, according to Downing. These genes encode proteins called transcription factors, which orchestrate the expression of a large number of other genes involved in B cell development. Together these genes coordinate the complex changes needed to induce progenitor cells to differentiate into B lymphocytes. In ALL, the leukemic cells fail to differentiate normally and instead remain blocked at an immature stage of development. Locked in this state, the leukemic cells continue to proliferate, and this continual growth of leukemic cells eventually kills the child.

"The new insights into the differentiation of B cells are extremely valuable," said Ching-Hon Pui, M.D., chair of the Oncology department and American Cancer Society Professor at St. Jude. Pui co-authored the paper. "The more we learn about why progenitor cells get stuck in the primitive, cancerous stage, the more likely we'll be able to design new therapies that eliminate them. That could help us continue our successful efforts to increase the su rvival rate of ALL."

One potential strategy for eliminating leukemic cells would take advantage of the discovery that mutations in the B-cell differentiation pathway are predicted to prevent progenitors from changing into normally functioning lymphocytes. Normally, the body eliminates differentiated B lymphocytes that have failed to assemble the right genes to make effective antibodies against the specific target they are supposed to attack. However, if these defective B lymphocytes do not differentiate because of the mutations, the body will not recognize them as defective immune cells and destroy them. Instead, these undifferentiated cells continue to multiply, causing ALL.

"If we could design a drug that bypasses the roadblock to differentiation, we could push these cells to become fully mature B lymphocytes," Downing said. "And then the body would recognize them as defective B lymphocytes and destroy them."


'"/>

Source:St. Jude Children's Research Hospital


Related biology news :

1. Major new UNC-based drinking water study suggests pregnancy fears may be overstated
2. Major breakthrough in the treatment of cancers and infectious diseases
3. Major advance made on DNA structure
4. Major WHO study concludes calcium supplements can reduce complications during pregnancy
5. Major obesity gene is lost in the shuffle
6. Major initiative proposed to address amphibian crisis
7. Major cancer study aims to identify protein markers for early-stage disease
8. Major link in brain-obesity puzzle found
9. Bioartificial kidney under study at MCG
10. W.M. Keck Foundation funds study of friendly microbes
11. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/16/2016)... Dec. 16, 2016 The global wearable medical device market, ... by 2021 from USD 5.31 billion in 2016, at a CAGR ... ... by technological advancements in medical devices, launch of a growing number ... wireless connectivity among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... , Dec. 15, 2016 ... driving experience, health wellness and wellbeing (HWW), ... one in three new passenger vehicles begin ... recognition, gesture recognition, heart beat monitoring, brain ... monitoring, facial monitoring, and pulse detection. These ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017  Northwell Health today announced ... of precision cancer research. As ... health care provider, Northwell Health diagnoses and treats ... is a Germany -based oncology ... Together they will greatly expand cancer biobanking activities ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... research, recently announced a collaboration with the Heidelberg University Hospital and the German ... library preparation, following the company’s successful launch of its CATS (Capture and ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... the prestigious Tibbetts Award from the U.S. Small Business Administration. The ... created a significant economic or social impact […] and are considered the best of ...
(Date:1/13/2017)... Jan 13, 2017 Research and Markets has announced ... their offering. ... biopolymers market to grow at a CAGR of 16.83% during the period ... growth prospects of the global biopolymers market for 2017-2021. To calculate the ... sales of biopolymer products. The report also includes a a discussion of ...
Breaking Biology Technology: